No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
FSNUY FRESENIUS SE&CO KGAA SPON ADR EA REP 0.25 ORD SHS
- 7.650
- -0.150-1.92%
15min DelayClose May 8 15:53 ET
17.24BMarket Cap-27031P/E (TTM)
7.760High7.550Low28.45KVolume7.550Open7.800Pre Close217.56KTurnover0.00%Turnover RatioLossP/E (Static)2.25BShares8.38052wk High0.84P/B17.24BFloat Cap6.33052wk Low0.26Dividend TTM2.25BShs Float13.684Historical High3.33%Div YieldTTM2.69%Amplitude4.631Historical Low7.648Avg Price1Lot Size
Post-Market
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Fresenius Guidance Lift, Vamed Restructuring in Focus -- Market Talk
0656 GMT - Fresenius's guidance lift and exit from its Vamed unit stood out among first-quarter results that beat market expectations, Jefferies analysts say. "While the market understood guidance to
Fresenius Lifts Guidance On Net Profit Beat
By Helena Smolak Fresenius lifted its full-year guidance on rising net profit that beat expectations in the first quarter, which was boosted by an improved performance of its core businesses Freseniu
Fresenius: Vamed's Hospital Services Unit to Be Transferred to Fresenius Group
Fresenius: Vamed's Hospital Services Unit to Be Transferred to Fresenius Group
Fresenius: Vamed's International Project Business to Gradually Be Scaled Back
Fresenius: Vamed's International Project Business to Gradually Be Scaled Back
Fresenius to Sell Vamed's Operations in Austria to Consortium
Fresenius to Sell Vamed's Operations in Austria to Consortium
Fresenius Exits Vamed
Fresenius Exits Vamed
Comments
We update our weekly tracker of the US IV generic market, focusing on sales and volumes for individual companies and the overall market, as well as providing analysis of individual products, which shows continued strong momentum for Kabi into August.
For the market overall, we observe a sequentially softer weekly print following a strong IV sales development in July, despite an easier comp. US generic injectable sales saw a modest c.+2% y/y in w/e August 4 (vs....
For the market overall, we observe a sequentially softer weekly print following a strong IV sales development in July, despite an easier comp. US generic injectable sales saw a modest c.+2% y/y in w/e August 4 (vs....
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg